Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
9-Amino-2-deoxy-2,3-dehydro-n-acetyl-neuraminic acid is a synthetic derivative of sialic acid and a structural analog of N-acetylneuraminic acid. It is classified as a small molecule and is primarily used in biochemical research as an experimental compound. This molecule acts as an inhibitor of neuraminidases (sialidases), enzymes that catalyze the removal of terminal sialic acids from glycoproteins and glycolipids on cell surfaces. By mimicking the transition state of the enzymatic reaction, it competitively inhibits both viral and mammalian neuraminidases[1][4][7]. This property makes it valuable for studying viral infection mechanisms (such as influenza) and cellular processes involving sialic acids. The compound has not been approved for clinical use or marketed under any brand name[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 9-Amino-2-deoxy-2,3-dehydro-n-acetyl-neuraminic acid.